454 related articles for article (PubMed ID: 11703838)
21. Visceral leishmaniasis (kala-azar): challenges ahead.
Singh RK; Pandey HP; Sundar S
Indian J Med Res; 2006 Mar; 123(3):331-44. PubMed ID: 16778314
[TBL] [Abstract][Full Text] [Related]
22. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
23. Leishmaniasis: current status of available drugs and new potential drug targets.
Singh N; Kumar M; Singh RK
Asian Pac J Trop Med; 2012 Jun; 5(6):485-97. PubMed ID: 22575984
[TBL] [Abstract][Full Text] [Related]
24. Visceral Leishmaniasis-Optimum Treatment Options in Children.
Sundar S; Agarwal D
Pediatr Infect Dis J; 2018 May; 37(5):492-494. PubMed ID: 29280784
[TBL] [Abstract][Full Text] [Related]
25. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
26. Drug combinations for visceral leishmaniasis.
Olliaro PL
Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
[TBL] [Abstract][Full Text] [Related]
27. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
Thakur CP; Narayan S; Ranjan A
Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
[TBL] [Abstract][Full Text] [Related]
28. Visceral leishmaniasis in children: a review.
Palumbo E
Minerva Pediatr; 2010 Aug; 62(4):389-95. PubMed ID: 20940672
[TBL] [Abstract][Full Text] [Related]
29. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
30. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
Kumar D; Kulshrestha A; Singh R; Salotra P
Antimicrob Agents Chemother; 2009 Feb; 53(2):835-8. PubMed ID: 19015344
[TBL] [Abstract][Full Text] [Related]
31. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis.
Carter KC; Sundar S; Spickett C; Pereira OC; Mullen AB
Antimicrob Agents Chemother; 2003 May; 47(5):1529-35. PubMed ID: 12709318
[TBL] [Abstract][Full Text] [Related]
32. Visceral leishmaniasis - current therapeutic modalities.
Sundar S; Chatterjee M
Indian J Med Res; 2006 Mar; 123(3):345-52. PubMed ID: 16778315
[TBL] [Abstract][Full Text] [Related]
33. Molecular Preadaptation to Antimony Resistance in Leishmania donovani on the Indian Subcontinent.
Dumetz F; Cuypers B; Imamura H; Zander D; D'Haenens E; Maes I; Domagalska MA; Clos J; Dujardin JC; De Muylder G
mSphere; 2018 Apr; 3(2):. PubMed ID: 29669889
[TBL] [Abstract][Full Text] [Related]
34. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
[TBL] [Abstract][Full Text] [Related]
35. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.
Guerin PJ; Olliaro P; Sundar S; Boelaert M; Croft SL; Desjeux P; Wasunna MK; Bryceson AD
Lancet Infect Dis; 2002 Aug; 2(8):494-501. PubMed ID: 12150849
[TBL] [Abstract][Full Text] [Related]
36. Treatment of visceral leishmaniasis: a review of current treatment practices.
Marty P; Rosenthal E
Expert Opin Pharmacother; 2002 Aug; 3(8):1101-8. PubMed ID: 12150689
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India.
Patra P; Guha SK; Maji AK; Saha P; Ganguly S; Chakraborty A; Kundu PK; Sarker S; Ray K
Indian J Pharmacol; 2012; 44(4):500-3. PubMed ID: 23087513
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
39. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
[TBL] [Abstract][Full Text] [Related]
40. Current treatment approaches to leishmaniasis.
Berman J
Curr Opin Infect Dis; 2003 Oct; 16(5):397-401. PubMed ID: 14501991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
